Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.285 SEK | -1.55% | -9.52% | -30.06% |
26/03 | Transcript : Vivesto AB - Special Call | |
07/03 | Vivesto AB Doses First Patient in its Clinical Paccal Vet Trial | CI |
Sales 2021 | 28.87M 2.64M 220M | Sales 2022 | 3.04M 278K 23.17M | Capitalization | 234M 21.34M 1.78B |
---|---|---|---|---|---|
Net income 2021 | -133M -12.16M -1.01B | Net income 2022 | -357M -32.63M -2.72B | EV / Sales 2021 | 37.7 x |
Net cash position 2021 | 86.84M 7.94M 662M | Net cash position 2022 | 134M 12.28M 1.02B | EV / Sales 2022 | 32.6 x |
P/E ratio 2021 |
-8.86
x | P/E ratio 2022 |
-0.6
x | Employees | 14 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 61.42% |
Latest transcript on Vivesto AB
1 day | -1.55% | ||
1 week | -9.52% | ||
Current month | -8.21% | ||
1 month | -10.80% | ||
3 months | -15.43% | ||
6 months | +31.34% | ||
Current year | -30.06% |
Managers | Title | Age | Since |
---|---|---|---|
Erik Kinnman
CEO | Chief Executive Officer | 66 | 23/23/23 |
Robert Maiorana
DFI | Director of Finance/CFO | 64 | 01/20/01 |
Heidi Ramstad
CTO | Chief Tech/Sci/R&D Officer | 55 | 01/21/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 44 | 19/19/19 | |
Hege Hellstrom
BRD | Director/Board Member | 59 | 26/19/26 |
Pål Ryfors
BRD | Director/Board Member | 41 | 25/22/25 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 0.285 | -1.55% | 492,006 |
25/24/25 | 0.2895 | -0.86% | 714,025 |
24/24/24 | 0.292 | -4.89% | 653,642 |
23/24/23 | 0.307 | -0.32% | 260,389 |
22/24/22 | 0.308 | -2.22% | 679,297 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 08:54 pm IST
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-30.06% | 13.99M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- VIVE Stock